More Data Needed To Assess Sinovac Jabs: Experts

"); jQuery("#212 h3").html("

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1570127_1_20210113184624.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1570127-20210113.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1570127-20210113.htm', 'DCS.dcsqry', '' ); } } }); }); });
2021-01-13 HKT 11:31
Medical experts on Wednesday said more data is needed to evaluate the efficacy of the coronavirus vaccine produced by mainland company Sinovac, in view of media reports that the jabs were found to be 50 percent effective during trials in Brazil.
Infectious disease specialist Joseph Tsang from Hong Kong Medical Association said the data released so far was preliminary and incomplete, and should be interpreted carefully.
"According to the media, the 50.4 per cent efficacy rate includes patients with mild symptoms and those asymptomatic carriers. So whether the asymptomatic carriers bring down the figures, we don't know at this point. So we have to get more data from Sinovac in order to interpret as a whole," he said.
Tsang said he also hoped to see more data collected from other countries which have used Sinovac vaccines, rather than just Brazil.
A specialist in respiratory medicine, Dr Leung Chi-chiu, said the figures available currently cannot be used to make apple-to-apple comparisons between coronavirus vaccines produced by different companies.
"We are not certain what these figures are talking about. There are multiple levels of efficacy. We can talk about efficacy against all infections. We can talk about efficacy against symptomatic infections. We can talk about efficacy against serious infections. All these have different meanings," he said.
"We need to look at the full data set before we can have a better guess of the actual situation and compare the efficacy between different vaccines," Leung said.
The Secretary for the Civil Service, Patrick Nip, meanwhile, said an expert panel appointed by the government would meet this week and review relevant clinical data.
Nip, who is one of the officials in charge of the vaccination programme to be rolled out in Hong Kong, said the panel would give clear advice on the matter later.
It is expected that Hong Kong people will start receiving coronavirus vaccinations in mid-February, with jabs produced by Sinovac being the first to arrive in the city.
HashKey Capital Partners With Tiantu AM To Explore Virtual Asset Funds
HashKey Capital has signed a memorandum of strategic collaboration with Tiantu Asset Management (Tiantu AM), a wholly o... Read more
You Can Now Make Alipay Payments With AR Glasses
RayNeo and Ant Group have announced a partnership to develop digital payment solutions for global use. The collaboratio... Read more
JICA Goes Live With Finastras Loan IQ In First Japan Deployment
Finastra has announced that the Japan International Cooperation Agency (JICA) has gone live with its Loan IQ platform. ... Read more
Japan Set To Approve First Yen-Backed Stablecoin
Japan’s Financial Services Agency (FSA) is preparing to approve the issuance of the country’s first yen-backed stab... Read more
Indonesia And China Begin Trials For Cross-Border QRIS Payments
Bank Indonesia (BI) and the People’s Bank of China (PBOC) have begun a series of trials for cross-border QR code paym... Read more
ANZ Appoints Ender Tanar As Japan Country Head
ANZ, headquartered in Melbourne, Australia, announced the appointment of Ender Tanar as Country Head for Japan, reporti... Read more